compounded glp-1

The Battle for Compounded GLP-1 Access: Regulatory Pressure, Litigation, and Affordability Executive Summary As of January 2026, the market for compounded GLP-1 receptor agonists—specifically semaglutide and tirzepatide—is at a volatile crossroads. Originally serving as a critical alternative...